Tech
By technologyCare
By clinical workflowOne offer, two ways to read it. Tech by technology type, Care by clinical benefit.
See the Milvue SuitePneumothorax, nodule, effusion, seen early.
The chest concentrates vital emergencies and screening. The Milvue Suite detects pneumothorax, opacities, pleural effusions and pulmonary nodules (Europe coverage), so nothing slips through the flow.
In short. On chest radiographs, the Milvue Suite flags pneumothorax, pleural effusions, opacities and nodules. In an independent study on 2,040 adults (Plesner et al., Radiology, 2023), its AUC is 0.97 for pneumothorax and 0.94 for pleural effusion. CE marked, Class IIa medical device in Europe; in the United States, SmartChest is FDA 510(k) cleared (K232410) for triage of pneumothorax and pleural effusion in adults.
The extra eye on every chest.
Chest detection flags and localizes pneumothorax, opacities, pleural effusions and pulmonary nodules.
- Pneumothorax and pleural effusion
- Opacities and pulmonary nodules
- AUC 0.97 for pneumothorax, 0.94 for pleural effusion (Plesner, Radiology, 2023)
- Exams with a finding move up the worklist
Three steps, no workstation change.
Nothing to change at the reading station: the solution slots into your existing flow.
Chest image
PA or lateral radiograph, no specific protocol.
Multi-pathology detection
Abnormalities localized, flagged as positive or doubtful.
Flag & report
Exams with a finding move up the worklist. Results insert into the report.
A very simple tool to use, easy to interpret, with an instant automated result, on the chest as on the skeleton.
At a glance.
CE-marked medical device, Class IIa, developed by Milvue. Native integration, protected data.
| Modalities | Chest radiography (PA / lat) |
|---|---|
| Pathologies | Pneumothorax, opacity, effusion, nodule |
| Population | Adult and pediatric · Europe coverage only |
| Output | Localized detection, returned on the image |
| Integration | Native RIS / PACS |
| Device | Milvue Suite, CE 2797, Class IIa (Europe) · SmartChest, FDA 510(k) cleared (US) |
Regulatory detail:
- Chest detection is part of TechCare Alert, in the Milvue Suite.
- The Milvue Suite software, developed by the Milvue company, is a Class IIa medical device within the meaning of EU Regulation MDR 2017/745 - Notified Body: BSI, CE 2797. TechCare Alert and TechCare Metrics are the commercial designations of its SmartUrgences® and SmartXpert® modules. Read the instructions for use carefully.
- SmartChest, developed by Milvue, is FDA 510(k) cleared (K232410) as a Class II device (21 CFR 892.2080). It is intended to aid clinicians and does not replace their judgment. Rx only. See the IFU for indications and warnings.
- Chest detection is not available in Canada.
Page updated on November 2, 2026.
Which chest findings does the Milvue Suite detect?
Pneumothorax, pleural effusions, opacities and nodules on chest radiographs (European coverage).
How does it perform on lung nodules?
In an independent validation of seven software products on 386 radiographs (van Leeuwen et al., Radiology, 2024), Milvue reached an AUC of 0.86, statistically above the mean of the 17 readers (0.81, p = 0.04).
Is chest detection cleared in the United States?
Yes, for triage: in the United States, SmartChest is FDA 510(k) cleared for triage of pneumothorax and pleural effusion in adults (K232410, May 2024). In Europe, chest detection is part of the Milvue Suite, a CE marked, Class IIa medical device.
See IFU.